Skip to main content
Premium Trial:

Request an Annual Quote

Konstantinos Andrikopoulos, Eric Olson

RXi Pharmaceuticals has named Konstantinos Andrikopoulos as vice president, legal counsel, and chief intellectual property officer.
Andrikopoulos was previously senior patent counsel for Shire Human Genetic Therapies. Before his time at Shire, he worked as a technology specialist, patent agent, and patent attorney for Wolf, Greenfield, and Sacks.
He holds a JD from Suffolk University Law School, a PhD in biomedical sciences from the City University of New York, and a BSc in biophysics from the University of East London.

Miragen Therapeutics said last week that its CSO and co-founder, Eric Olson, was awarded the American Heart Association National Research Achievement Award.
Olson is also a professor and chairman of the molecular biology department at the University of Texas Southwestern Medical Center. The award was given to him for his work in identifying molecular mechanisms that control normal and abnormal growth and development of the heart and cardiovascular system, Miragen said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.